A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 01 May 2011
At a glance
- Drugs CHS 131 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors InteKrin Therapeutics
- 15 Jun 2009 New trial record.
- 10 Jun 2009 The primary endpoint "fasting glucose level" has been met, according to a InteKrin media release.
- 06 Jun 2009 Results presented at the 68th Annual Scientific Sessions of the American Diabetes Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History